79,345 Orion Corporation A Shares Converted Into B Shares
Date
1/13/2025 3:00:52 AM
(MENAFN- GlobeNewsWire - Nasdaq) ORION CORPORATION
STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE
13 JANUARY 2025 at 9.50 EET
79,345 Orion Corporation A shares converted into B shares
In accordance with Section 3 of the Articles of Association of Orion Corporation, 79,345 A shares have been converted into 79,345 B shares. The conversion has been entered into the Trade Register on 13 January 2025.
The total number of shares in Orion Corporation is 141,134,278 which, after the conversion, consists of 32,752,263 A shares and 108,382,015 B shares. The number of votes of the company's shares is after the conversion 763,427,275.
Orion Corporation
René Lindell
CFO | | Olli Huotari
SVP, Corporate Functions |
|
Contact person :
Tuukka Hirvonen, Investor Relations, tel. +358 10 426 2721
Publisher :
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2023 amounted to EUR 1,190 million and the company had about 3,600 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.
MENAFN13012025004107003653ID1109082682
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.